. Author manuscript; available in PMC: 2020 Jun 24.

Published in final edited form as: Med Res Arch. 2020 May 25;8(5):2091. doi: 10.18103/mra.v8i5.2091

Table 3:

Clinical trials evaluating neoadjuvant, perioperative, & adjuvant immunotherapies for renal cell carcinoma.

Trial	Treatments	Setting (doses)	Stage for Inclusion	Histology	Primary Endpoint
Checkmate 914 NCT03138512	Ipilimumab + Nivolumab	Adjuvant (24 weeks)	pT2a (G3/4), ≥pT2b TanyN1M0	Primarily clear cell	DFS
RAMPART NCT03288532	Durvalumab ± Tremelimumab	Adjuvant D only (13 cycles) D+T (13+2 cycles)	Leibovich score 3–11	Any RCC histology	DFS, OS
KEYNOTE-564 NCT03142334	Pembrolizumab	Adjuvant (17 cycles)	pT2 (G3, sarcomatoid) ≥pT3, pTanyN+M0 (any G) M1 NED	Clear cell RCC (including sarcomatoid)	DFS
IMmotion010 NCT03024996	Atezolizumab	Adjuvant (16 cycles)	pT2 (G4), pT3 (G3/4), ≥pT3b, pTxN+, M1 NED	Clear cell RCC (including sarcomatoid)	DFS
NEOAVAX NCT03341845	Axitinib + Avelumab	Neoadjuvant (12 weeks)	High-risk nonmetastatic RCC	Clear cell RCC	Partial response
PROSPER NCT03055013	Nivolumab	Neoadjuvant (1 dose) Adjuvant (9 doses)	≥T2Nx or TanyN+ or M1^*	Any RCC histology	RFS

G: Grade; DFS: disease-free survival; OS: overall survival; RFS: recurrence-free survival

M1 disease has be resected/definitively treat at the same time or within 12-week window of surgical intervention such as that patient is considered “No Evidence of Disease”